english.prescrire.org > Prescrire International > N°252 - October 2023

n°252

October 2023

Issue Contents
Editorial

Free  No regard for patients!

p.227

Marketing Authorisations


Rimegepant (Vydura°) in migraine

p.229-232

Editors' opinion. Placebomania

p.231

Ruxolitinib (Jakavi°) in graft-versus-host disease, after failure of at least one immunosuppressant

p.233-234

Enfortumab vedotin (Padcev°) as third, or subsequent, treatment line for urothelial carcinoma

p.235-237

Dupilumab (Dupixent°) in severe asthma from 6 years of age

p.237-238

Lenacapavir (Sunlenca°) in multidrug-resistant HIV-1 infection

p.239-241

Inset. Pharmacological classes of the main anti­retroviral drugs on the European market as of 7 April 2023

p.240

Somatrogon (Ngenla°) in growth disturbance

p.241

Risperidone as monthly injections (Okedi°)

p.242

The fate of pseudoephedrine is in the hands of the European Medicines Agency

p.243

Adverse Effects


Cannabidiol: sometimes serious adverse effects, and multiple drug interactions

p.244

Antiviral drugs for hepatitis C: arrhythmias and cardiac conduction disorders, even after treatment cessation

p.245

Isoniazid: mania

p.245

Contraceptive implants containing etonogestrel: more cases of migration to the pulmonary artery, and pregnancies

p.246

Methotrexate: cutaneous ulceration as a sign of overdose

p.246

Misoprostol and pregnancy: malformations

p.247

Common stem: som-

p.247

Outlook


Drug shortages: patients lose out, healthcare professionals waste time

p.248-249

Free  Prescrire a cosignatory of letters to various European institutions

p.250

Emergency Use Authorization of covid-19 tests by the FDA: failings

p.250-251

Free  Publication of clinical trial protocols

p.251

Masthead


Free  Masthead

p.226

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe